Envista Holdings (NVST) AI Stock Analysis

• Market Cap: $3.53B
• Dividend Yield: N/A
• Average Volume (3M): 1.89M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: -2.30%
• EPS Growth: -854.21%
• Country: US
• Employees: 12,300
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Equipment & Services
• EPS (TTM): 0.24
• Shares Outstanding: 169,487,010
• 10 Day Avg. Volume: 1,914,880
• 30 Day Avg. Volume: 1,890,620
• PEG Ratio: 4.94
• Price to Book (P/B): 1.12
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 12.54
• Enterprise Value/Market Cap: 1.09
• Enterprise Value/Revenue: 0.38
• Enterprise Value/Gross Profit: 2.83
• Enterprise Value/Ebitda: -0.95
• 1Y Price Target: $19.93
• Price Target Upside: -3.91% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 57 Neutral
• Price Target: $19.00 ▼(-8.39%Downside)

Envista Holdings shows strengths in technical momentum and cash flow generation, but faces significant challenges in profitability and valuation. The potential for operational improvements and strategic initiatives provides some positive outlook, but risks from leverage and external challenges in China and foreign exchange remain high.

Positive Factors

Earnings Performance

NVST beat consensus revenue and earnings in 1Q25 and management reiterated its 2025 revenue and EPS guidance.

Growth Potential

There is potential for Envista to grow at the high-end of the 2-4% core revenue growth target in the medium term.

Tariff Management

Management highlighted it has less tariff exposure vs. peers given its made-local, for-local philosophy and should avoid the negative sentiment/multiple contraction that has weighed on peer performance recently.

Negative Factors

Dental Market Conditions

The dental demand environment is still soft, with declines in consumer confidence levels.

Geographical and Product Line Weakness

Certain geographies and product lines remain weak, such as diagnostics declines in North America and China, and declining challenger implants globally.

Uncertainty and Exposure

Uncertainty over macro conditions and tariffs creates new headwinds for the company.

Envista Holdings Business Overview & Revenue Model

Company Description

Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. The firm provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The firm operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Its Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.

How the Company Makes Money

Envista Holdings makes money primarily through the sale of its dental products and solutions to dental professionals and organizations worldwide. The company's revenue streams are predominantly driven by its Specialty Products & Technologies segment, which includes high-margin products like dental implants and orthodontic solutions. The Equipment & Consumables segment contributes significantly as well, with products such as digital imaging tools and essential dental consumables. Envista also benefits from strategic partnerships and collaborations with dental professionals and institutions, which help to expand its market reach and drive sales. Additionally, the company invests in ongoing research and development to innovate and maintain a competitive edge in the dental industry.

Envista Holdings Financial Statement Overview

Summary

Envista Holdings faces financial challenges with negative profitability and inconsistent revenue growth. While the balance sheet offers stability through healthy equity, rising leverage is a concern. Positive cash flow generation is a strength, though it is impacted by negative net income.

Income Statement

Envista Holdings has experienced fluctuations in profitability with negative net income in recent periods. The gross profit margin remains fairly stable, indicating decent control over cost of goods sold. However, the negative EBIT and EBITDA margins in the TTM period highlight operational inefficiencies. Revenue growth has been inconsistent, with recent declines contributing to overall instability.

Balance Sheet

The company's balance sheet shows a healthy equity position relative to its total assets, suggesting solid financial backing. However, a rising debt-to-equity ratio poses a risk, reflecting increased leverage that could impact future financial flexibility. The return on equity has been adversely affected by negative net income, limiting shareholders' returns.

Cash Flow

Envista Holdings demonstrates a relatively strong cash flow position, with consistent positive operating cash flow. Free cash flow remains positive but shows signs of decline, indicating potential challenges in sustaining cash generation. The operating cash flow to net income ratio is favorable, suggesting effective cash conversion from operations, though negative net income affects the overall assessment.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.51B	2.57B	2.57B	2.51B	2.28B
Gross Profit	1.37B	1.45B	1.47B	1.43B	1.16B
EBITDA	-883.80M	171.10M	484.40M	460.50M	205.60M
Net Income	-1.12B	-100.20M	243.10M	263.50M	33.30M
Balance Sheet
Total Assets	5.35B	6.61B	6.59B	6.57B	6.88B
Cash, Cash Equivalents and Short-Term Investments	1.07B	940.00M	606.90M	1.07B	888.90M
Total Debt	1.55B	1.65B	1.53B	1.46B	1.98B
Total Liabilities	2.42B	2.43B	2.38B	2.52B	3.15B
Stockholders Equity	2.93B	4.17B	4.21B	4.06B	3.72B
Cash Flow
Free Cash Flow	302.70M	217.50M	107.00M	336.70M	236.20M
Operating Cash Flow	336.50M	275.70M	182.70M	391.40M	283.90M
Investing Cash Flow	-54.60M	-62.40M	-657.30M	232.90M	-69.10M
Financing Cash Flow	-103.70M	118.90M	12.50M	-465.60M	492.50M

Envista Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 20.74
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVST, the sentiment is Positive. The current price of 20.74 is above the 20-day moving average (MA) of 20.13, above the 50-day MA of 19.14, and above the 200-day MA of 19.00, indicating a bullish trend. The MACD of 0.40 indicates Negative momentum. The RSI at 63.10 is Neutral, neither overbought nor oversold. The STOCH value of 85.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVST.

Envista Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LH	75 Outperform	$22.17B	29.20	9.27%	1.10%	7.98%	72.22%
PDCO	70 Outperform	$2.77B	20.21	14.15%	2.49%	-0.85%	-23.40%
SHC	65 Neutral	$3.49B	142.03	5.88%	―	2.78%	-54.72%
SGRY	62 Neutral	$2.72B	―	-10.43%	―	13.54%	-30732.00%
XRAY	62 Neutral	$3.19B	―	-34.47%	3.99%	-5.61%	-921.99%
NVST	57 Neutral	$3.53B	―	-31.33%	―	-2.30%	-854.21%
Sector *	52 Neutral	$7.65B	0.16	-63.14%	2.08%	16.38%	0.82%

Envista Holdings Corporate Events

Envista Holdings Expands Board with New Appointment

On July 14, 2025, Envista Holdings Corporation expanded its Board of Directors by appointing J. Andrew Pierce, increasing the board size from eight to nine members. Mr. Pierce, who has been with Stryker Corporation since 1996 in various leadership roles, will serve on the Board until the 2026 Annual Meeting of Stockholders and has been appointed to the Audit Committee. His appointment led to an update in the composition of the Board’s committees, and he will receive standard compensation and equity awards for non-employee directors.

The most recent analyst rating on (NVST) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Envista Holdings stock, see the NVST Stock Forecast page.

Envista Holdings Holds 2025 Annual Stockholders Meeting

On June 10, 2025, Envista Holdings held its 2025 Annual Meeting of Stockholders, where several key proposals were voted on. The stockholders elected directors for a one-year term, ratified the appointment of Ernst & Young LLP as the independent registered public accountant, approved executive compensation, and authorized an amendment to increase shares under the Omnibus Incentive Plan, reflecting ongoing governance and strategic planning efforts.

The most recent analyst rating on (NVST) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Envista Holdings stock, see the NVST Stock Forecast page.